

Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

Francisco Mesonero¹, Yamile Zabana, Agnès Fernández-Clotet, Eduardo Leo-Carnerero, Berta Caballol, Andrea Núñez-Ortiz, María José García², Federico Bertoletti, Alejandro Mínguez, Gerard Suris, Begoña Casis, Rocío Ferreiro-Iglesias, Margalida Calafat³, Itxaso Jiménez, José Miranda-Bautista, Luis Javier Lamuela, Ingrid Fajardo, Leyanira Torrealba, Rodrigo Nájera, Rosa María Sáiz-Chumillas, Irene González, Miren Vicuña, Natalia García-Morales, Ana Gutiérrez, Alicia López-García, José Manuel Benítez, Cristina Rubín de Célix, Coral Tejido, Eduard Brunet, Alejandro Hernández-Camba, Cristina Suárez, Iago Rodríguez-Lago, Marta Piqueras, Andrés Castaño, Laura Ramos⁴, Ana Sobrino, María Carmen Rodríguez-Grau, Alfonso Elosua, Miguel Montoro, Ruth Baltar, José María Huguet, Benito Hermida, Antonio Caballero-Mateos, Luis Sánchez-Guillén, Abdel Bouhmidi, Ramón Pajares, Iria Baston-Rey, Antonio López-Sanromán, Agustín Albillos and Manuel Barreiro-de Acosta
On behalf of the GETECCU Young Members Group

Abstract

Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders.

Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders.

Design: This was a retrospective and multicentre study.

Methods: We included patients diagnosed with inflammatory pouch disorders treated with azathioprine in monotherapy. Effectiveness was evaluated at 1 year and in the long term based on normalization of stool frequency, absence of pain, faecal urgency or fistula discharge (clinical remission), or any improvement in these symptoms (clinical response). Endoscopic response was evaluated using the Pouchitis Disease Activity Index (PDAI).

Results: In all, 63 patients were included [54% males; median age, 49 (28–77) years]. The therapy was used to treat pouchitis ($n=37$) or Crohn's disease of the pouch ($n=26$). The rate of clinical response, remission and non-response at 12 months were 52%, 30% and 18%, respectively. After a median follow-up of 23 months (interquartile range 11–55), 19 patients (30%) were in clinical remission, and 45 (66%) stopped therapy. Endoscopic changes were evaluated in 19 cases. PDAI score decreased from 3 (range 2–4) to 1 (range 0–3). In all, 21 patients (33%) presented adverse events and 16 (25%) needed to stop therapy.

Conclusion: Azathioprine may be effective in the long term for the treatment of inflammatory pouch disorders and could be included as a therapeutic option.

Keywords: azathioprine, immunosuppressants, pouchitis, thiopurines

Received: 16 November 2023; revised manuscript accepted: 2 February 2024.

Ther Adv Gastroenterol

2024, Vol. 17: 1–12

DOI: 10.1177/
17562848241234476

© The Author(s), 2024.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:
Francisco Mesonero
Inflammatory Bowel
Disease Unit, Department
of Gastroenterology and
Hepatology, Hospital
Universitario Ramón y
Cajal, Cra. Colmenar km
9.1, Madrid 28034, Spain
pacomeso@hotmail.com

Yamile Zabana
Hospital Universitario
Mútua Terrassa, Terrassa,
Spain

Centro de Investigación
Biomédica en Red de
Enfermedades Hepáticas
y Digestivas (CIBERehd),
Madrid, Spain

Agnès Fernández-Clotet
Berta Caballol
Hospital Clínic Barcelona,
Institut d'Investigacions
Biomèdiques August
Pi i Sunyer (IDIBAPS),
Barcelona, Spain

Centro de Investigación
Biomédica en Red de
Enfermedades Hepáticas
y Digestivas (CIBERehd),
Madrid, Spain

Eduardo Leo-Carnerero
Andrea Núñez-Ortiz
Hospital Universitario
Virgen del Rocío, Sevilla,
Spain

María José García
Hospital Universitario
Marqués de Valdecilla,
IDIVAL, Santander, Spain

Federico Bertoletti
Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain

Alejandro Mínguez
Hospital Universitario
y Politécnico La Fe,
Valencia, Spain

Gerard Suris
Hospital Universitario de
Bellvitge, Barcelona, Spain

Begoña Casis

Hospital Universitario 12 de Octubre, Madrid, Spain

Rocío Ferreiro-Iglesias

Iria Baston-Rey

Manuel Barreiro-de

Acosta

Hospital Clínico Universitario Santiago, Santiago de Compostela, Spain

Margalida Calafat

Hospital Universitario Germans Trias i Pujol, Badalona, Spain

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [CIBERehd], Madrid, Spain

Itxaso Jiménez

Iago Rodríguez-Lago

Hospital Universitario de Galdakao, Biocruces Bizkaia Health Research Institute, Galdakao, Spain

José Miranda-Bautista

Hospital Universitario Gregorio Marañón, Madrid, Spain

Luis Javier Lamuela

Hospital Universitario Miguel Servet, Zaragoza, Spain

Ingrid Fajardo

Hospital Universitario Mútua Terrassa, Terrassa, Spain

Leyanira Torrealba

Hospital Universitario Doctor Josep Trueta, Girona, Spain

Rodrigo Nájera

Hospital Universitario Río Hortega, Valladolid, Spain

Rosa María Sáiz-Chumillas

Hospital Universitario Burgos, Burgos, Spain

Irene González

Hospital Universitario Puerta de Hierro, Madrid, Spain

Miren Vicuña

Complejo Hospitalario Navarra, Pamplona, Spain

Natalia García-Morales

Hospital Álvaro Cunqueiro, Vigo, Spain

Ana Gutiérrez

Hospital General Universitario Alicante Doctor Balmis (Alicante), Instituto de Investigación Sanitaria y Biomédica de Alicante [ISABIAL], Alicante, Spain

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [CIBERehd], Madrid, Spain

Alicia López-García

Hospital del Mar i Institut Mar d'Investigacions Mèdiques [IMIM], Barcelona, Spain

Introduction

Restorative proctocolectomy with ileal pouch–anal anastomosis remains the gold-standard procedure for the surgical treatment of ulcerative colitis (UC).^{1,2} Pouchitis is a non-specific inflammatory disorder that affects some pouch patients. While its aetiology remains unknown, it has been associated with risk factors such as the previous presence of inflammatory bowel disease (IBD).^{3–5} In fact, pouchitis is the most frequent non-mechanical complication in pouch patients with UC [prevalence, 29% (8–41%)].^{4–8}

Clinical manifestations include increased stool frequency, faecal urgency, bloody diarrhoea and abdominal pain. Pouchitis can manifest as an acute, recurrent or chronic disease that interferes with quality of life.⁷ Inflammatory pouch disorders other than pouchitis, such as cuffitis and Crohn's disease (CD) of the pouch, may also appear.^{8–10} Cuffitis involves inflammation of the rectal cuff and resembles ulcerative proctitis.¹¹ CD of the pouch is a heterogeneous entity that includes inflammation of the pouch and/or the afferent ileal limb and may give rise to complications such as the stricturing and fistulizing phenotypes beyond 6–12 months after pouch surgery.^{12,13} CD of the pouch could be present in up to 25% of pouch patients.^{13–16}

The therapeutic approach to inflammatory pouch disorders has been poorly explored, and many recommendations are based on non-controlled studies.^{17–20} The recommended treatment of pouchitis, cuffitis and CD of the pouch includes antibiotics,^{21–23} mesalamine, oral budesonide²⁴ and biological therapy.^{25–29} However, the absence of studies on pouchitis and other inflammatory pouch disorders treated with immunosuppressants such as azathioprine means that these drugs are not included in the therapeutic arsenal despite their known effectiveness and role as steroid-sparing agents in IBD. Given the unmet needs in the management of inflammatory pouch disorders, it would be interesting to know the role of azathioprine in this scenario.

Therefore, the main objective of this study was to assess the long-term effectiveness of azathioprine prescribed for pouch inflammatory disorder treatment. We also assessed endoscopic findings, duration of treatment, safety and long-term outcomes.

Methods

Study design and endpoints

This was an observational, retrospective and multicentre nationwide study undertaken by the Young Members Group of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU).

We selectively identified pouch patients aged 18 years or older who had undergone surgery between 1995 and 2020. All patients had been diagnosed with UC (resection specimen with compatible histology) and subsequently with inflammatory pouch disorders (pouchitis, CD of the pouch or cuffitis) following the diagnostic criteria of the European Crohn's and Colitis Organization, GETECCU and the International Ileal Pouch Consortium (IIPC).^{9,10,15} The conditions were being treated with azathioprine in monotherapy based on clinical decisions. Pouchitis was classified according to the criteria of the IIPC (acute, chronic, recurrent or antibiotic-responsive).¹⁵ We excluded patients who received these therapies for other clinical indications (e.g. extraintestinal manifestations or as part of a solid organ transplant immunosuppressant regimen), patients who were taking azathioprine in combination with biological therapy and patients who were lost to follow-up after initiation of therapy.

The demographic and clinical characteristics of the patients were recorded based on the Montreal and the IIPC classification. Perianal fistulas, strictures and penetrating complications were recorded if they appeared 6–12 months after stoma closure. We also recorded the presence of extraintestinal manifestations (articular, ocular, cutaneous, hepatic and other).^{15,30} Prior treatments and the indication for azathioprine therapy were also collected.

Participants were followed until withdrawal of therapy or their last clinical visit.

The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology statement.³¹

Definitions

Effectiveness was evaluated using clinical definitions. Clinical remission was defined as the

normalization of stool frequency (this was the recovery of basal stool frequency) with the absence of abdominal pain, rectal bleeding, faecal urgency or cessation of fistula drainage. Clinical response was defined as any improvement in these parameters (over clinical worsening) without remission. Non-response was defined as no change in symptoms.^{25–29} This evaluation was used for pouchitis and CD of the pouch. We only considered that patients had experienced a clinical response and remission provided they were not receiving concomitant steroid therapy. Changes in endoscopic activity were evaluated (only for patients with baseline endoscopy assessment) using the endoscopic sub-score of the modified Pouchitis Disease Activity Index (PDAI).³²

Effectiveness was evaluated at 12 months and to the maximum follow-up. Treatment was discontinued in the case of non-response, loss of remission/response, adverse events, maintained remission and patient decision.

Finally, we also analysed the persistence of therapy defined as the time under active treatment.

Statistical analysis

In the descriptive analysis, categorical variables were expressed as absolute and relative frequencies. Quantitative variables were expressed as the mean and standard deviation (SD) or as the median and interquartile range (IQR) when they were not normally distributed. In the univariate analysis, categorical variables were compared using the chi-square test, and quantitative variables were compared using the appropriate test depending on the normality of the distribution. Factors that were found to be significantly associated with clinical response and remission were further explored in a multivariate logistic regression analysis with the odds ratio and 95% confidence interval. Persistence of therapy was assessed by the Kaplan–Meier method whereby patients in whom therapy was discontinued for any reason were right-censored at the time of discontinuation. Variables were included in the analysis if their *p* value was <0.1 . Statistical significance was set at $p < 0.05$ for the rest of the statistical analysis. The analysis was performed using IBM SPSS Statistics for Windows, Version 24.

Results

Patient baseline characteristics

The cohort of the RESERVO study comprised 338 patients with inflammatory pouch disorder from 46 centres in Spain. A total of 93 patients from this cohort (27%) were treated with immunosuppressants. We excluded 25 patients who started immunosuppressants as combination therapy with biologics and 5 treated with other immunosuppressants (cyclosporine, methotrexate and tacrolimus). After applying the inclusion/exclusion criteria, the final study cohort consisted of 63 patients (Figure 1).

The main demographic and disease-related characteristics of the study patients are provided in Table 1. Before therapy, 59 (94%) of participants had received antibiotics; of these, 65% were refractory or dependent. In all, 28 (46%) patients received probiotics (failure in 43%, recurrence in 13%), 37 (64%) rectal and/or oral mesalamine (38% without response) and 30 (50%) oral and/or topical steroids (29% were refractory, 42% developed dependence and 2 stopped due to adverse events). No patients received biological therapy before azathioprine for the treatment of their pouch disorders.

Treatment characteristics

The indications for azathioprine therapy were a CD of the pouch (25, 40%), recurrent pouchitis (20, 32%) and antibiotic-refractory pouchitis (17, 27%). None of the patients who received this treatment presented cuffitis.

As previously mentioned, 50% of patients had previously been exposed to steroids, and they experienced refractoriness or dependence in 29% and 42%, respectively. Therapy was started at a median of 23 months (IQR 7–190 months) after the diagnosis of pouch disorder and this was longer for patients diagnosed with CD of the pouch (median, 89 months, IQR 25–205, difference 66 months, IQR 15–112 ($p = 0.002$)).

Effectiveness of azathioprine

A total of 63 patients received azathioprine as monotherapy. The standard dose used was 2.5 mg/kg/day. At 12 months, 19 patients (30%) were in clinical remission and 33 (52%) had

José Manuel Benítez
Hospital Universitario
Reina Sofía, Córdoba,
Spain

Cristina Rubín de Célix
Hospital Universitario de
La Princesa, Instituto de
Investigación Sanitaria
Princesa (IIS-Princesa),
Universidad Autónoma
de Madrid (UAM), Madrid,
Spain

Centro de Investigación
Biomédica en Red de
Enfermedades Hepáticas
y Digestivas (CIBERehd),
Madrid, Spain

Coral Tejido
Complejo Hospitalario
Universitario Ourense,
Ourense, Spain

Eduard Brunet
Hospital Universitario Parc
Taulí, Sabadell, Spain
Centro de Investigación
Biomédica en Red de
Enfermedades Hepáticas
y Digestivas (CIBERehd),
Madrid, Spain

Alejandro Hernández-Camba
Hospital Universitario
Nuestra Señora de
Candelaria, Santa Cruz,
Spain

Cristina Suárez
Hospital Universitario
La Paz, Instituto de
Investigación Sanitaria del
Hospital Universitario La
Paz (IdiPAZ), Madrid, Spain

Marta Piqueras
Consorcio Sanitario
Terrassa, Terrassa, Spain

Andrés Castaño
Hospital Universitario
Central Asturias, Oviedo,
Spain

Laura Ramos
Hospital Universitario
de Canarias, Santa Cruz,
Spain

Ana Sobrino
Hospital General
Universitario Ciudad Real,
Ciudad Real, Spain

Maria Carmen Rodríguez-Grau
Hospital Universitario del
Henares, Coslada, Spain

Alfonso Elosua
Hospital García Orcoyen,
Estella, Spain

Miguel Montoro
Hospital General
Universitario San Jorge,
Huesca, Spain

Ruth Baltar
Hospital Universitario
Álava, Vitoria, Spain

José María Huguet
Hospital General
Universitario Valencia,
Valencia, Spain

Benito Hermida
Hospital Universitario
Cabueñes, Gijón, Spain

Antonio Caballero-Mateos
Hospital Santa Ana Motril,
Motril, Spain

Luis Sánchez-Guillén
Hospital General
Universitario Elche, Elche,
Spain

Abdel Bouhmid
Hospital Santa Bárbara,
Puertollano, Spain

Ramón Pajares
Hospital Universitario
Infanta Sofía, San
Sebastián de los Reyes,
Spain

Antonio López-Sanromán
Agustín Albillos
Hospital Universitario
Ramón y Cajal, Madrid,
Spain




Figure 1. Flowchart of population included.

achieved a clinical response. In all, 11 patients (18%) achieved no response.

No differences in clinical response, clinical remission or non-response at 1 year were detected for various indications (recurrent pouchitis *versus* antibiotic-refractory pouchitis *versus* CD of the pouch). The only factor associated with clinical response and/or remission in the univariate analysis was steroid-dependent disease as the indication for azathioprine (85% *versus* 15%, $p=0.01$) (Table 2). Therefore, the multivariable analysis was not performed.

In long term, after a median follow-up of 23 months (IQR 11–55) from the start of azathioprine, 19 patients (30%) were in clinical remission, 21 (33%) had achieved a clinical response and 12 (19%) who had initially experienced a clinical response/remission lost their response.

Finally, the persistence of azathioprine is represented in Figure 2. The percentage of patients

who maintained treatment was 66%, 59% and 48% at 1, 2 and 3 years.

A total of 42 (66%) patients stopped therapy due to failure [non-response/remission or loss of response; 20 (47.6%)], adverse events (16, 38%) and sustained remission (6, 14%).

Re-evaluation of endoscopic activity

Endoscopic activity was re-evaluated in 19 patients (30%). After a median 9 months of endoscopic follow-up, the median PDAI endoscopic sub-score dropped from 3 (range 2–5) to 1 (range 0–5) ($p=0.020$) (Figure 3). Histological data were not systematically obtained and could not be analysed.

Safety

A total of 21 patients (33%) experienced adverse events secondary to azathioprine (Table 3). Finally, 16 (25%) patients were forced to stop therapy due to adverse effects.

Table 1. Demographic and disease-related characteristics of patients treated with azathioprine.

Basal characteristics	Patients, <i>N</i> =63 (%)
Male sex	34 (54)
Age (median, range)	49 (28–77)
Age at colectomy (median, range)	31 (18–59)
Smoking (never/current/former)	49/4/10 (78/6/16)
Indication for colectomy	Failure of medical treatment, 37 (59)
	Acute severe flare, 22 (35)
	Dysplasia cancer, 3 (5)
	Lower gastrointestinal bleeding, 1 (2)
J-type ileal pouch–anal anastomosis	63 (100)
Inflammatory pouch disorder	Pouchitis, 37 (59)
	Crohn's disease pouch, 26 (41)
Months between ileostomy closure and pouch disorder (median, range)	7 (0–72)
Classification of pouchitis (<i>n</i> =37)*	Acute, 4 (11)
	Chronic, 33 (89)
	Recurrent, 36 (97)
	Antibiotic dependent, 10 (28)
	Antibiotic refractory, 16 (44)
Location of Crohn's disease (<i>n</i> =26)	Pouch, 22 (85)
	Ileal pre-pouch, 25 (96)
	Upper disease, 4 (15)
Disease behaviour (Montreal B1/B2/B3)	18/6/2 (69/23/8)
Perianal disease	8 (31)
Extraintestinal manifestations	19 (30)
Primary sclerosing cholangitis	3 (5)
Optimal azathioprine dose (2.5 mg/kg)	63 (100)
*Acute (<4 weeks of symptoms), chronic (≥4 weeks of symptoms), recurrent and antibiotic dependent (≥3–4 episodes per year). ¹⁵	
B1, inflammatory; B2, stricturing; B3, penetrating.	


Duration and outcomes

The median follow-up was 23 months (IQR 11–55). A total of 42 patients (66%) suspended therapy due to failure (20, 32%), adverse events (16, 25%) and sustained remission (6, 9%). After

treatment withdrawal, 6 patients received another immunosuppressant, and 36 patients started biological therapy. Nevertheless, 22 patients needed pouch surgery owing to treatment refractoriness and, finally, 16 required a permanent ileostomy.


Table 2. Factors associated with clinical response and remission at 1 year: results of univariate analysis.

Variables	Clinical remission/response (%)		OR (95% CI)	p Value
	Yes	No		
Smoking (active smoker)	5 (3.2)	1 (0)	3.6 (0.4–32)	0.247
Extraintestinal manifestations	13 (19)	6 (9.5)	1.17 (0.5–2.9)	0.578
Pouch disorder diagnosed				
Pouchitis	24 (65)	13 (35)	0.7 (0.3–1.7)	0.306
Crohn's disease	14 (54)	12 (46)		
Behaviour of Crohn's				
B1	7 (39)	9 (56)	0.25 (0.1–1.7)	0.184
B2–3	5 (50)	5 (50)		
Perianal disease	6 (67)	3 (33)	1.6 (0.4–6.6)	0.391
Pouch disorder with an indication for therapy:				
Recurrent pouchitis	13 (62)	8 (38)	0.92 (0.3–2.7)	0.792
Antibiotic-refractory pouchitis	11 (65)	6 (35)		
Previous steroid use	18 (56)	14 (44)	0.8 (0.3–1.9)	0.486
Steroid dependency	11 (85)	2 (15)	6.13 (1.4–26)	0.01

**Figure 2.** Persistence of azathioprine, survival analysis.

Discussion

To our knowledge, this nationwide study comprises the largest series to date of pouch patients with IBD and subsequent inflammatory pouch

**Figure 3.** Endoscopic activity changes.

disorders (mainly chronic pouchitis) treated with azathioprine. One in four patients from the RESERVO study used this drug as a therapeutic option, even before biological therapy, resulting in an effective long-term strategy in around two-thirds of patients. However, half of them interrupted therapy for several reasons.

Table 3. Adverse events associated with azathioprine (N=63).

Adverse event	n [%]
Myelotoxicity	8 [12.7]
Digestive intolerance	4 [6.3]
Fever	1 [1.6]
Neoplasm*	2 [3]
Acute pancreatitis	1 [1.6]
Liver toxicity	2 [3]
Systemic CMV infection	1 [1.6]
Other	2 [3]
*Ovarian neoplasm, leukaemia. CMV, citomegalovirus.	

Various pharmacologic options are available for the management of inflammatory pouch disorders. However, published data are often scarce, and the strongest recommendations are based on antibiotic and/or biological therapy.^{9,18,19} Although immunosuppressants such as thiopurines and methotrexate have proven effective in the management of CD and UC, these drugs have been poorly explored in the case of pouch disorders, although they may be more widely used than previously thought.³³ To date, only two studies have evaluated the effectiveness of thiopurines in CD of the pouch (two case reports and a short clinical series of eight patients).^{34,35} Based on this evidence, GETECCU¹⁸ recommended against the use of immunosuppressants in the case of chronic refractory pouchitis. However, clinical experience with thiopurines has been reported, since many studies that have evaluated the effectiveness of biological therapy in pouch disorders included patients previously exposed to thiopurines.^{25,26,28,29,36} Consensus guidelines from the IIPC are also based on limited evidence in favour of immunosuppressants for chronic pouchitis and CD of the pouch; nevertheless, the authors suggest the potential use of immunosuppressants (thiopurines) as monotherapy with a low grade of evidence, supported mainly by expert opinion.¹⁹ This is supported as thiopurines are used in IBD, an entity that shares many characteristics with pouch inflammatory disorders.³⁷

Our results show that azathioprine seems an interesting additional option in patients with

inflammatory pouch disorders even in the biological era (in this series, more than 60% of patients received this treatment after 2010, data not shown). We found this therapy was associated with clinical response and remission during the first year in more than 80% of cases and with clinical remission in the long term in 30% of cases. The profile of patients in this study includes those whose previous treatment (antibiotics, mesalamine, probiotics and steroids) had failed. It is important to highlight that azathioprine was chosen as a therapeutic option first than biological therapy. This was a clinical decision and it could be due to several reasons such as clinical experience with thiopurines or the scarce and limited evidence of biological therapy in previous decades among others.

Azathioprine was especially useful for previously steroid-dependent patients, with 84% long-term steroid-free clinical remission and response. However, two out of three patients needed to stop therapy in the long term owing to non-response (32%) or adverse events (25%), and more than half switched to biological therapy.

Our findings lead us to ask how to include and position thiopurines in the treatment algorithm of inflammatory pouch disorders. However, thiopurines are not an appropriate choice for inducing remission. Biological therapy is a good therapeutic option in patients with chronic refractory pouchitis and CD of the pouch.^{25–29,33,36,38} One meta-analysis reported that clinical remission after induction of anti-TNF agents was more common in CD than in chronic pouchitis (64% *versus* 10%).²⁷ Nonetheless, our data show that they would be a useful alternative long-term option, especially for patients with previous exposure to steroids who develop dependence (85% *versus* 15%, $p=0.01$). Considering effectiveness and safety data, the different maintenance therapeutic options should be discussed and balanced with the patient.

The patients in our cohort achieved similar clinical benefits with azathioprine, irrespective of the type of inflammatory pouch disorder [chronic recurrent (62%), refractory (64%) and CD of the pouch (60%)]. In their single-centre study of 21 patients with CD of the pouch, Haveran *et al.* reported infliximab and/or azathioprine to be effective.³⁴ Eight patients received thiopurines in monotherapy, and the success of treatment was

defined as complete resolution of or significant improvement in symptoms without requiring ileostomy. Treatment proved successful for all patients after a median of 38 months. This excellent result may be because physicians selected patients who received thiopurines in monotherapy instead of biological therapy or, even, combination therapy.

Finally, safety is one of the most relevant factors in therapy with azathioprine. In our study, 33% of patients presented adverse events, mainly affecting the haematological and digestive systems. More than three out of four were forced to stop therapy because of the event. These results resembled those reported in the literature and could limit the use of this therapy in many cases.³⁹ However, there are several strategies to optimize the management of azathioprine (some of them to improve tolerance) that have not been analysed in this study and could be related to the high rate of discontinuation. We did not evaluate whether patients were exposed to azathioprine before colectomy or whether they had tolerated treatment previously.

This study is subject to a series of limitations. First, the design was retrospective and the number of patients included was limited to obtain firm conclusions. Nevertheless, pouchitis and other pouch inflammatory disorders are uncommon diseases within IBD. Second, baseline clinical activity and effectiveness were not evaluated using scores such as the PDAI or modified PDAI: the retrospective nature of this study meant that we used a less standardised definition, as analysed in many previously published studies.^{25–29} Moreover, none of these activity indices have previously been validated. A recent expert consensus group used a RAND/UCLA process to help clinicians and investigators assess the activity of pouchitis based on clinical factors such as stool frequency, faecal urgency and endoscopic and histological activity.⁴⁰ In our cohort, 19 patients (30%) were also evaluated using endoscopy, which revealed a decrease in the PDAI sub-score. On the other hand, ours is the first publication to date to report the effectiveness of azathioprine in inflammatory pouch disorders and to include a relevant number of patients belonging to a large multicentre and nationwide cohort affected by a rare condition within IBD. Furthermore, it enabled us to explore future options for this complex scenario.

In conclusion, the therapeutic arsenal for inflammatory pouch disorders remains open to various pharmacologic options. Azathioprine would also be a feasible maintenance therapeutic option for these disorders, especially in the case of steroid dependence. Further studies may confirm our findings and position these old but effective drugs appropriately.

Declarations

Ethics approval and consent to participate

The study design and its procedures were approved by the Clinical Research Ethics Committee of the steering centre, Hospital Universitario Ramón y Cajal (Madrid, Spain) with approval number 156/20 and the research committee of GETECCU. Written informed consent to participate in the study was obtained from all patients.

Consent for publication

All participants reviewed and approved the manuscript and gave their consent for publication.

Author contributions

Francisco Mesonero: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Writing – original draft; Writing – review & editing.

Yamile Zabana: Formal analysis; Methodology; Project administration; Supervision; Validation; Writing – review & editing.

Agnès Fernández-Clotet: Data curation; Writing – review & editing.

Eduardo Leo-Carnerero: Data curation; Writing – review & editing.

Berta Caballol: Data curation.

Andrea Núñez-Ortiz: Data curation.

María José García: Data curation; Visualization; Writing – review & editing.

Federico Bertolotti: Data curation; Visualization; Writing – review & editing.

Alejandro Mínguez: Data curation; Visualization.

Gerard Suris: Data curation.

Begoña Casis: Data curation; Visualization; Writing – review & editing.

Rocío Ferreira-Iglesias: Conceptualization; Methodology; Visualization; Writing – review & editing.

Margalida Calafat: Data curation; Visualization.

Itxaso Jiménez: Data curation.

José Miranda-Bautista: Data curation; Visualization; Writing – review & editing.

Luis Javier Lamuela: Data curation.

Ingrid Fajardo: Data curation.

Leyanira Torrealba: Data curation.

Rodrigo Nájera: Data curation.

Rosa María Sáiz-Chumillas: Data curation.

Irene González: Data curation.

Miren Vicuña: Data curation.

Natalia García-Morales: Data curation.

Ana Gutiérrez: Data curation; Visualization.

Alicia López-García: Conceptualization; Data curation; Methodology; Validation; Visualization; Writing – review & editing.

José Manuel Benítez: Data curation; Visualization; Writing – review & editing.

Cristina Rubín de Célix: Data curation; Visualization; Writing – review & editing.

Coral Tejido: Data curation.

Eduard Brunet: Data curation; Visualization; Writing – review & editing.

Alejandro Hernández-Camba: Data curation; Visualization.

Cristina Suárez: Data curation; Visualization; Writing – review & editing.

Iago Rodríguez-Lago: Conceptualization; Methodology; Visualization; Writing – review & editing.

Marta Piqueras: Data curation; Visualization.

Andrés Castaño: Data curation.

Laura Ramos: Data curation.

Ana Sobrino: Data curation.

María Carmen Rodríguez-Grau: Data curation; Visualization.

Alfonso Elosua: Data curation; Visualization.

Miguel Montoro: Data curation; Visualization.

Ruth Baltar: Data curation.

José María Huguet: Data curation.

Benito Hermida: Data curation.

Antonio Caballero-Mateos: Data curation.

Luis Sánchez-Guillén: Data curation.

Abdel Bouhmid: Data curation.

Ramón Pajares: Data curation.

Iria Baston-Rey: Data curation; Visualization.

Antonio López-Sanromán: Conceptualization; Supervision; Validation; Visualization; Writing – review & editing.

Agustín Albillos: Validation.

Manuel Barreiro-de Acosta: Conceptualization; Formal analysis; Methodology; Project administration; Supervision; Validation; Writing – review & editing.

Acknowledgements

The authors thank the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) for sponsoring this study.

Funding

The authors received no financial support for the research, authorship and/or publication of this article.

Competing interests

Francisco Mesonero has served as a speaker for and received consulting fees from MSD, AbbVie, Takeda, Janssen, Pfizer, Ferring, Kern-Pharma, Dr. Falk Pharma, Galapagos, Chiesi and Faes Farma. Yamile Zabana has received support for conference attendance, speaker fees, research support and consulting fees from AbbVie, Adacyte, Almirall, Amgen, Dr. Falk Pharma, FAES Pharma, Ferring, Janssen, MSD, Otsuka, Pfizer, Shire, Takeda, Galapagos, Boehringer Ingelheim and Tillots. Agnés Fernández-Clotet has served as a speaker for and received educational funding from Dr. Falk Pharma, Janssen, Takeda, Chiesi and Pfizer. Eduardo Leo-Carnerero has served as a speaker and consultant for and received educational funding from AbbVie, Janssen, Takeda, Ferring, Gilead, Pfizer and Dr. Falk Pharma. Andrea Núñez-Ortiz has

received educational funding from Janssen, Takeda, Ferring and Pfizer. Berta Caballol has served as a speaker for and received consulting fees from MSD, AbbVie, Janssen, Takeda, Ferring, Shire Pharmaceuticals and Faes Pharma. Rocío Ferreiro-Iglesias has received support for conference attendance, speaker fees, research support and consulting fees from AbbVie, Adacyte, Dr. Falk Pharma, FAES Pharma, Ferring, Janssen, MSD, Kern, Chiesi, Gebro Pharma, Pfizer, Shire, Takeda and Tillots. José Miranda-Bautista has received support for conference attendance, speaker fees, and consulting and advisory fees from AbbVie, Adacyte, Dr. Falk Pharma, FAES Pharma, Ferring, Janssen, Pfizer, Takeda and Tillots. Leyanira Torrealba has served as a speaker for and received educational funding from AbbVie, Janssen, Takeda, Ferring, Gilead, Pfizer, Dr. Falk Pharma and Tillots Pharma. Rosa María Sáiz-Chumillas has served as a speaker for and received consulting fees from Janssen, Ferring and Faes Farma. Alicia López-García has received support for conference attendance, educational funding and speaker fees from Chiesi, AbbVie, Janssen, Ferring, Takeda, Pfizer and Tillots. Cristina Rubín de Céliz has received educational funding from Ferring, Tillots Pharma, AbbVie, Norgine, MSD, Pfizer, Takeda and Janssen and is supported by a grant from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, Rio Hortega CM21/00025) and co-financed by the European Social Fund Plus (ESF+) 'Co-financed by the European Union'. Eduard Brunet has served as a speaker and consultant for and received educational funding from Janssen, Takeda, Ferring, Kern-Pharma, AbbVie and Chiesi. Alejandro Hernández-Camba has served as a speaker for and received educational funding from AbbVie, Takeda, Kern Pharma, Pfizer, Janssen, Adacyte Therapeutics, Chiesi, Galapagos and Ferring. Iago Rodríguez-Lago has received financial support for travelling and educational activities from or has served as an advisory board member for AbbVie, Adacyte, Celltrion, Chiesi, Danone, Dr. Falk Pharma, Ferring, Faes Farma, Janssen, Galapagos, MSD, Otsuka Pharmaceutical, Pfizer, Roche, Takeda and Tillots Pharma. Iago Rodríguez-Lago has also received financial support for research from Tillots Pharma and is supported by a research grant from Gobierno Vasco – Eusko Jaurlaritza [Grant No. 2020222004]. Alfonso Elosua has served as a speaker for and has received educational funding from AbbVie,

Adacyte, Takeda, FAES Farma, Ferring, Janssen and Tillots Pharma. José María Huguet has received fees for educational activities, research projects, scientific meetings and advisory boards sponsored by MSD, Ferring, AbbVie, Janssen, Biogen, Sandoz, Kern Pharma, Faes Farma and Takeda. Manuel Barreiro-de Acosta has served as a speaker, consultant and advisory member for and has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gilead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma.

Availability of data and materials

The data underlying this article will be shared on reasonable request to the corresponding author.

Guarantors of the article

Francisco Mesonero, Yamile Zabana and Manuel Barreiro-de Acosta are the guarantors of the article.

ORCID iDs

Francisco Mesonero  <https://orcid.org/0000-0002-7864-8187>

María José García  <https://orcid.org/0000-0002-6517-7005>

Margalida Calafat  <https://orcid.org/0000-0003-2335-3792>

Laura Ramos  <https://orcid.org/0000-0001-7015-1742>

References

1. Scoglio D, Ahmend Ali U and Fichera A. Surgical treatment of ulcerative colitis: ileorectal vs ileal pouch-anal anastomosis. *World J Gastroenterol* 2014; 20: 13211–13218.
2. Parks AG and Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. *Br Med J* 1978; 2: 85–88.
3. Shen B. Acute and chronic pouchitis-pathogenesis, diagnosis and treatment. *Nat Rev Gastroenterol Hepatol* 2012; 9: 323–333.
4. Fazio VW, Kiran RP, Remzi FH, *et al.* Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. *Ann Surg* 2013; 257: 679–685.
5. Dozois RR, Kelly KA, Welling DR, *et al.* Ileal pouch-anal anastomosis: comparison of results

- in familial adenomatous polyposis and chronic ulcerative colitis. *Ann Surg* 1989; 210: 268–271.
6. Hueting WE, Buskens E, van der Tweel I, *et al.* Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9371 patients. *Dig Surg* 2005; 22: 69–79.
 7. Barnes EL, Herfarth HH, Sandler RS, *et al.* Pouch-related symptoms and quality of life in patients with ileal pouch-anal anastomosis. *Inflamm Bowel Dis* 2017; 23: 1218–1224.
 8. Peyrin-Biroulet L, Germain A, Patel AS, *et al.* Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. *Aliment Pharmacol Ther* 2016; 44: 807–816.
 9. Magro F, Gionchetti P, Eliakim R, *et al.* Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery and ileo-anal pouch disorders. *J Crohns Colitis* 2017; 11: 649–670.
 10. Barreiro de-Acosta M, Gutierrez A, Rodríguez-Lago I, *et al.* Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. *Gastroenterol Hepatol* 2019; 42: 568–578.
 11. Wu B, Lian L, Li Y, *et al.* Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses. *Inflamm Bowel Dis* 2013; 19: 404–410.
 12. Shen B. Crohn's disease of the ileal pouch: reality, diagnosis and management. *Inflamm Bowel Dis* 2009; 15: 284–294.
 13. Lightner AL, Pemberton JH, Loftus EJ, *et al.* Crohn's disease of the ileoanal pouch. *Inflamm Bowel Dis* 2016; 22: 1502–1508.
 14. Barnes EL, Kochar B, Jessup HR, *et al.* The incidence and definition of Crohn's disease of the pouch: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2019; 25: 1474–1480.
 15. Shen B, Kochhar GS, Kariv R, *et al.* Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. *Lancet Gastroenterol Hepatol* 2021; 6: 826–849.
 16. Shamah S, Schneider J and Korelitz BI. High incidence of recurrent Crohn's disease following colectomy for ulcerative colitis revealed with long follow-up. *Dig Dis Sci* 2018; 63: 446–451.
 17. Dalal RL, Shen B and Schwartz DA. Management of pouchitis and other common complications of the pouch. *Inflamm Bowel Dis* 2018; 24: 989–996.
 18. Barreiro-de Acosta M, Marín-Jimenez I, Rodríguez-Lago I, *et al.* Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. *Gastroenterol Hepatol* 2020; 43:649–658.
 19. Shen B, Kochhar GS, Rubin DT, *et al.* Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. *Lancet Gastroenterol Hepatol* 2022; 7: 69–95.
 20. Singh S, Stroud AM, Holubar SD, *et al.* Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Cochrane Database Syst Rev* 2015; 23: CD001176.
 21. Shen B, Achkar JP, Lashner BA, *et al.* A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. *Inflamm Bowel Dis* 2001; 7: 301–305.
 22. Gionchetti P, Rizzello F, Venturi A, *et al.* Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. *Aliment Pharmacol Ther* 1999; 13: 713–718.
 23. Madden MV, McIntyre AS and Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. *Dig Dis Sci* 1994; 39: 1193–1196.
 24. Gionchetti P, Rizzello F, Poggioli G, *et al.* Oral budesonide in the treatment of chronic refractory pouchitis. *Aliment Pharmacol Ther* 2007; 25: 1231–1236.
 25. Barreiro-de Acosta M, García-Bosch O, Souto R, *et al.* Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. *Inflamm Bowel Dis* 2012; 18: 812–817.
 26. Barreiro-de Acosta M, García-Bosch O, Gordillo J, *et al.* Efficacy of adalimumab rescue therapy in patients with refractory pouchitis previously treated with infliximab: a case series. *Eur J Gastroenterol Hepatol* 2012; 24: 756–758.
 27. Huguet M, Pereira B, Goutte M, *et al.* Systematic review with meta-analysis: anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal

- anastomosis following colectomy for ulcerative colitis. *Inflamm Bowel Dis* 2018; 24: 261–268.
28. Colombel JF, Ricart E, Loftus EV Jr, *et al.* Management of Crohn's disease of the ileoanal pouch with infliximab. *Am J Gastroenterol* 2003; 98:2239–2244.
29. Ferrante M, D'Haens G, Dewit O, *et al.* Efficacy of Infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. *Inflamm Bowel Dis* 2010; 16: 243–249.
30. Silverberg MS, Satsangi J, Ahmad T, *et al.* Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; 19(Suppl. A): 5A–36A.
31. von Elm E, Altman DG, Egger M, *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147: 573–577.
32. Shen B, Achkar JP, Connor JT, *et al.* Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. *Dis Colon Rectum* 2003; 46: 748–753.
33. Núñez L, Mesonero F, Rodríguez de Santiago E, *et al.* High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified. *Gastroenterol Hepatol* 2023; 46: 369–375.
34. Haveran LA, Sehgal R, Poritz LS, *et al.* Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA. *Dis Colon Rectum* 2011; 54: 15–20.
35. Berrebi W, Chaussade S, Bruhl AL, *et al.* Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine. *Dig Dis Sci* 1993; 38: 1558–1560.
36. Bermejo F, Aguas M, Chaparro M, *et al.* Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. *Gastroenterol Hepatol* 2018; 41: 205–221.
37. Yadav A, Foromera J, Falchuk KR, *et al.* Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature. *Scand J Gastroenterol* 2018; 53: 813–817.
38. Chandan S, Mohan BP, Kumar A, *et al.* Safety and efficacy of biological therapy in chronic antibiotic refractory pouchitis: a systematic review with meta-analysis. *J Clin Gastroenterol* 2021; 55: 481–491.
39. Chaparro M, Ordás I, Cabré E, *et al.* Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. *Inflamm Bowel Dis* 2013; 19: 1404–1410.
40. Sedano R, Ma C, Pai RK, *et al.* An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. *Aliment Pharmacol Ther* 2021; 53: 1108–1117.